南京大学医学院-j9集团

李婕博士学位
主任医师
电话:邮箱:lijier@nju.edu.cn 地址:南京市鼓楼区中山路321号研究方向:

脂肪性肝病、病毒性肝炎的发病机制及临床诊疗

  • 个人简介
  • 学术兼职
  • 代表性论文
  • 承担科研项目
  • 获奖情况

        南京大学医学院附属鼓楼医院   感染性疾病科主任

        主任医师,研究员,医学博士,博士后,教授、博士研究生导师。

        2011年毕业于浙江大学,获内科学专业博士学位。2015年获香港大学郑裕彤博士奖助金资助前往香港大学肝病学研究国家重点实验室,从事病毒性肝炎的基础研究。2016年在美国斯坦福大学医学中心师从著名肝病学家mindie h. nguyen教授,从事脂肪性肝病发病机制研究。

        近年来,与美国斯坦福大学、香港大学、浙江大学、北京大学建立了良好的合作交流关系,参与多项国内、外多中心合作研究项目。作为课题负责人主持国家自然科学基金3项及国家科技重大专项(十三五)(子任务)课题、教育部科技发展中心高校产学研创新基金、中国博士后科学基金、山东省自然科学基金项目(面上、重点)、山东省重点研发计划项目、中国肝炎防治基金会项目、济南市科技发展计划项目、南京市医学重点科技发展项目共17项,参与2项国家十一五重大专项,1项973项目,3项国家自然科学基金的研究工作,并作为子课题负责人参与美国斯坦福大学牵头的国际多中心real-c研究项目。获批国家发明专利2项,获山东省医学科技二等奖(第一位)、山东省科技进步二等奖(第三位)、华夏医学科技奖三等奖(第三位)、山东省高等学校科学技术奖一等奖(第四位)各一项。发表sci论文102篇,其中以第一作者/通讯作者在the lancet gastroenterology & hepatologyprotein & celljama network openhepatologyclin gastroenterol hepatoamerican journal of gastroenterologydiabetes care等国际权威杂志发表sci论文58篇,h指数29,累计影响因子455分,其中大于10分文章16篇,最高影响因子45分,累计他引1200次,3篇入选esi高被引文章,单篇最高引用率561次。主(参)编论(译)著5部。相关研究成果多次受邀在欧洲肝病年会、亚太肝病年会、美国消化疾病周、美国肝病年会等国际著名肝病会议进行口头汇报交流,发表会议论文20篇。2018年获山东省首届称号。2018年获山东省立医院首届中青年创新人才称号。2019年获山东省立医院“科研先进个人”。2020年获山东省立医院“诚仁科研奖励基金”。2022年获“江苏特聘医学专家”称号。2023年获“江苏省双创人才”称号



学术兼职:中华医学会肝病学分会青年委员,中国研究型医院学会肝病专业委员会常委、中国研究型医院学会肝病专业委员会脂肪肝和酒精肝学组副组长,中华医学会肝病学分会脂肪肝和酒精性肝病学组委员,江苏省医师协会感染病分会副会长,江苏省中西医结合学会理事,江苏省医学会感染病分会委员,江苏省中西医结合学会肝病专业委员会常委,中华医学会内科学分会临床循证医学学组委员,中国研究型医院学会分子诊断医学委员会肝病精准诊断与治疗学组委员,美国肝脏研究协会会员,肝病临床思维训练营青年委员。


  杂志编委:《山东大学学报(医学版)》、《中国肝脏病杂志》、《临床肝胆病杂志》、《实用肝胆病杂志》《中华实验和临床感染病杂志》、《gut(中文版)》、《j clin transl hepatol》、《therapeutic advances in chronic disease》、《frontiers in molecular biosciences


1)      jie li, biyao zou, yee hui yeo, yuemin feng, xiaoyu xie, dong hyun lee,

hideki fujii, yuankai wu, leslie y. kam, fanpu ji, xiaohe li, nicholas chien, mike wei, eiichi ogawa, changqing zhao, xia wu, christopher d. stave, linda henry, scott barnett, hirokazu takahashi, norihiro furusyo, yuichiro eguchi, yao-chun hsu, teng-yu lee, wanhua ren, chengyong qin, dae won jun, hidenori toyoda, vincent wai-sun wong,ramsey cheung, qiang zhu, mindie h. nguyen. prevalence, incidence, and outcome of non-alcoholic fatty liver disease in asia, 1999-2019: a systematic review and meta-analysis. the lancet gastroenterology & hepatology..doi: 10.1016/s2468-1253(19)30039-1. (if=45.042)(中科院分区:1区)(esi高被引论文)

2)      jie li, huang dq, zou b, yang h, hui wz, rui f, yee nts, liu c, nerurkar sn, kai jcy, teng mlp, li x, zeng h, borghi ja, henry l, cheung r, nguyen mh. epidemiology of covid-19: a systematic review and meta-analysis of clinical characteristics, risk factors and outcomes. j med virol. 2021 mar;93(3):1449-145. doi: 10.1002/jmv.26424. (if=20.693) (中科院分区:3区)(esi高被引论文)

3)      yingrui wang#, qianru zhu#, rui sun#, xiao yi#, lingling huang, yifan hu, weigang ge, huanhuan gao, xinfu ye, yu song, li shao, yantao li, jie li*, tiannan guo*, junping shi* longitudinal proteomic investigation of covid-19 vaccination. protein & cell. 2023 sep 14;14(9):668-682. doi: 10.1093/ procel/ pwad004. (if=21.1)(中科院分区:1区)(共同通讯作者)

4)      fajuan rui#, yee hui yeo#, liang xu#, qi zheng, xiaoming xu, wenjing ni, youwen tan, qing-lei zeng, zebao he, xiaorong tian, qi xue, yuanwang qiu, chuanwu zhu, weimao ding, jian wang, rui huang, yayun xu, yunliang chen, junqing fan, zhiwen fan, xiaolong qi, daniel q. huang, qing xie*, junping shi*, chao wu‡, jie li*. development of a machine learning-based model to predict hepatic inflammation in chronic hepatitis b patients with concurrent hepatic steatosis: a cohort study. eclinicalmedicine.2023 (if=15.1)(中科院分区:1区)

5)      jiawen zhou, xinyue sun, xuelian chen, huimin liu, xiulian miao, yan guo, zhiwen fa, jie li*, yong xua*, zilong li*. phosphatidic acid-enabled mkl1 contributes to liver regeneration: translational implication in liver failure. 2023 (if=14.5)(中科院分区:1区)(共同通讯作者)

6)      yee hui yeo*, yixuan zhu*, juan pablo arab, wenjing ni, xiaoming xu, junping shi#, jie li#. alcohol intake thresholds in individuals with steatotic liver disease. jama network open 2023 (if=13.8)(中科院分区:1区)

7)      yin s#, wan y#, issa r, zhu y, xu x, liu j, mao m, li m, tong x, tian c, wang j, huang r, zhang q, wu c*, chen y*, jie li*. the presence of baseline hbsab-specific b cells can predict hbsag or hbeag seroconversion of chronic hepatitis b on treatment. emerg microbes infect. 2023 sep 13:2259003. doi: 10.1080/22221751.2023.2259003 (if=13.2)(中科院分区:2区)

8)      jie li, michael h. le, monique t. barakat, ramsey c. cheung, mindie h. nguyen. the changing epidemiology of liver disease among united states children and adolescents from 1999-2016. american journal of gastroenterology. 2021 oct 1;116(10):2068-2078. doi: 10.14309/ ajg.0000000000001386. (if=12.045)(中科院分区:1区)

9)      jie li, ramsey c. cheung, nonalcoholic fatty liver disease in children: where are we? clinical gastroenterology and hepatology. 2022 oct;20(10):2210-2215.doi: 10.1016/j.cgh.2022.02.008. (if=13.576)(中科院分区:1区)

10)   xiaoming xu, mindie h nguyen, jie li. chronic hepatitis b and steatotic liver disease: a blessing in disguise? clinical gastroenterology and hepatology. 2024 (if=13.576)(中科院分区:1区)

11)   zebaohe, jie li, comment on cai et al. obesity and covid-19 severity in a designated hospital in shenzhen, china. diabetes care. 2020; 43:1392-1398 (letter). diabetes care. 2020;43:e160–e161.doi:10.2337/dc20-1195. (if=19.112)(中科院分区:1区)通讯作者

12)   jie li, ramsey c. cheung, mindie h. nguyen, letter to the editor: chronic hepatitis b and nonalcoholic steatohepatitis: is fat all bad? hepatology. 2020;71:768. doi: 10.1002/hep.30983.(if=17.298)(中科院分区:1区)

13)   jie li, mindie h. nguyen,screening for fatty liver disease and fibrosis in the elderly population: a call for action. hepatology. 2023 feb 1;77(2): e28-e29.doi: 10.1002/hep.32727. (if=17.298)(中科院分区:1区)

14)   jie li, mindie h. nguyen. chronic hepatitis b and fatty liver-weal or woe? american journal of gastroenterology. 2022 apr 1;117(4):688. doi: 10.14309/ajg.0000000000001644. (if=12.045)(中科院分区:1区)

15)   run zhou, binbin zhang, yunpeng gu, jie li*, junping shi*. a promising digital therapeutics for nonalcoholic steatohepatitis: more efforts are needed. am j gastroenterol. american journal of gastroenterology. 2023 sep 1;118(9):1704-1705.doi: 10.14309/ajg.0000000000002244. (if=12.045)(中科院分区:1区)(共同通讯作者)

16)   jie li, feng chen, min zheng, haihong zhu, dongjiu zhao, weixia liu, wei liu, chen zhi. inhibition of stat1 methylation is involved in the resistance of hepatitis b virus to interferon alpha, antiviral research. 2010 (85) 463-469. doi: 10.1016/j.antiviral.2009.10.011. (if=10.101)(中科院分区:2区)

17)yin s, wang j, chen l, mao m, rahma i, geng y, huang r, tong x, liu y, wu c*, chen y*, jie li*. circulating th2-biased t follicular helper cells impede antiviral humoral responses during chronic hepatitis b infection through upregulating ctla4. antiviral research. 2023 jul 6:105665. doi: 10.1016/j.antiviral.2023.105665. (if=10.101) (中科院分区:2区)

18)   zhiwen fan, xinyue sun, xuelian chen, huimin liu, xiulian miao, yan guo, yong xu, jie li*, xiaoping zou*, zilong li*. c-c motif chemokine ccl11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease. jhep reports. 2023 may 26;5(9):100805 doi: 10.1016/j.jhepr.2023.100805. (if=9.917)(中科院分区:1区)共同通讯作者

19)   jie li, ha audrey, rui fajuan, zou biyao, yang hongli, xue qi, hu xinyu, xu yayun, henry linda, barakhat  monique, stave christopher, shi jun-ping, wu chao, cheung ramsey, mindie h. nguyen. meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. alimentary pharmacology & therapeutics. 2022 aug;56 (3):396-406.doi: 10.1111/apt.17096. (if=9.524)(中科院分区:1区)

20)   xu x, liu j, wu c, jie li. letter: to expand the diagnosis and scale up treatment for patients with chronic hepatitis b-difficult but necessary. aliment pharmacol ther. 2023 may;57(10):1201-1202.doi: 10.1111/apt.17470. (if=9.524)(中科院分区:1区)

21)   jie li, an k. le, kevin t. chaung, linda henry, joseph k. hoang, ramsey cheung, mindie h. nguyen. fatty liver is not independently associated with rates of complete response to oral antiviral therapy in chronic hepatitis b patients, . 2020;40:1052-1061.doi: 10.1111/liv.14415. (if=8.754)(中科院分区:2区)

22)   jie li, lung yi mak, danny wong, james y. y. fung, wai-kay seto, ching lung lai, man fung yuen, the role of interleukin-27 in predicting spontaneous hbeag seroconversion in chronic hepatitis b infection, . 2017 sep;37(9):1287-1294. doi: 10.1111/liv.13372. (if=8.754)(中科院分区:2区)

23)   jie li, mindie h. nguyen, non-alcoholic fatty liver disease (nafld) in asia-more efforts are needed. .2020 dec;40 (12):3144. doi: 10.1111/liv.14657. (if=8.754)通讯作者(中科院分区:2区)

24)   jie li, mindie h. nguyen, noninvasive diagnosis methods are needed in paediatric non-alcoholic fatty liver disease (nafld). .2021 may;41(5):1161. doi: 10.1111/liv.14748. (if=8.754)(中科院分区:2区)

25)   jie li, hwai-i yang, ming-lun yeh, an k. le, yee hui yeo, chia-yen dai, scott barnett, jian q. zhang, jee-fu huang,huy n. trinh, christopher wong, clifford wong, joseph k.hoang, ramsey cheung, ming-lung yu, mindie h. nguyen. association between fatty liver and cirrhosis, hepatocellular carcinoma, and hbsag seroclearance in chronic hepatitis b. journal of infectious diseases. 2021 jul 15;224(2):294-302. doi: 10.1093/infdis/jiaa739. (if=7.759)(中科院分区:2区)

. hepatology international.2023  (if=6.6)(中科院分区:2区)

27)   shao l#, liu j#, song y#, yang w, gong l, lyu z, zhu q, fu j*, jie li*, shi j*. serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (mafld). clin chim acta. 2023 jan 1;538:203-210.doi: 10.1016/j.cca.2022.12.014 (if=6.314)(中科院分区:2区)共同通讯作者

28)   xin tong, shengxia yin, jian wang, rui huang, chao wu, jun ping shi, jie li. clinical impact and mechanisms of hepatitis b virus infection concurrent with non-alcoholic fatty liver disease. chinese medical journal (engl). 2022 jul 20;135(14):1653-1663. doi: 10.1097/cm9.0000000000002310. (if=6.013) (中科院分区:2区)通讯作者

29)   jie li, adèle delamarre, vincent wai-sun wong, victor de lédinghen. diagnosis and assessment of disease severity in patients with nonalcoholicfatty liver disease. united european gastroenterology journal. 2023 (if=6.0) (中科院分区:2区)

30)   jie li#, xinyu hu#, xuein yan#,wu c, yuemin nan. clinical characteristics and possible etiology in children with acute severe hepatitis of unknown etiology. chinese medical journal (engl). chin med j (engl). 2022 dec 20; 135 (24):3019-3021. doi: 10.1097/cm9.0000000000002445. (if=6.013)(中科院分区:2区)

31)   binbin zhang#, jie li#, jinlong fu, luping yang, junping shi.interaction between the mucus layer and the gut microbiota in nafld: soil and seeds. chinese medical journal (engl). 2023 jun 20;136(12):1390-1400. doi: 10.1097/cm9.0000000000002711. (if=6.013)(中科院分区:2区)

32)   jie li, wei wu, guoping peng, feng chen, minghui bai, min zheng and zhi chen. hbcag induces interleukin 10 production, inhibiting hbcag-specific th17 responses in chronic hepatitis b patients. immunology and cell biology. 2010 nov-dec;88(8):834-41.doi: 10.1038/icb.2010.63. (if=5.853)(中科院分区:3区)

33)   zhan j, wang j, zhang z, xue r, jiang s, liu j, liu y, zhu l, xia j, yan x, ding w, zhu c, qiu y, jie li*, huang r*, wu c*. noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis b in the indeterminate phase. virulence. 2023 dec;14(1):2268497. doi: 10.1080/21505594.2023.2268497. epub 2023 nov 8. pmid: 37938933; pmcid: pmc10653690. (if=5.2)(中科院分区:2区)(共同通讯作者)

34)   jie li, jian-gao fan. characteristics and mechanism of liver injury in 2019 coronavirus disease. j clin transl hepatol. 2020;8(1):13-17. doi: 10.14218/jcth.2020.00019. (if=5.065)esi高被引论文)(中科院分区:2区)

35)   chuanli liu, hongli yang, yuemin feng, cuihong liu, fajuan rui, yuankui cao, xinyu hu, jiawen xu, junqing fan, qiang zhu, jie li. a knn model to predict the early recurrence of hepatocellular carcinoma (hcc) after resection. j clin transl hepatol. 2022 aug 28;10(4):600-607. doi: 10.14218/jcth.2021.00348. (if=5.065)(中科院分区:2区)

36)   jian wang#, jiacheng liu#, yilin liu#, ruifei xue, jie zhan, suling jiang, li wang, xiaomin yan, yali xiong, juan xia, shengxia yin, xin tong, yuxin chen, jie li*, rui huang*, chao wu*. clinical features of chronic hepatitis b patients with lean non-alcoholic fatty liver disease. hepatology research. 2023 mar;53(3):184-195. doi: 10.1111/hepr. (if=4.942)(中科院分区:2区)(共同通讯作者)

37)    hu x, sun l, guo z, wu c, yu x, jie li, management of covid-19 patients with chronic liver diseases and liver transplants. ann hepatol. 2022 jan-feb;27(1):100653. doi: 10.1016/j.aohep.2021.100653. (if=3.8)(中科院分区:4区)通讯作者

38)   zhou r, gu y, zhang b, kong t, zhang w, jie li,* shi j*. digital therapeutics: emerging new therapy for nonalcoholic fatty liver disease. clin transl gastroenterol. 2023 apr 1;14(4):e00575.(if=3.6)(中科院分区:3区)共同通讯作者

39)   jie li, wanhua ren, wei ma, jiao zhang, jun shi, chengyong qin, interleukin-21 responses in patients with chronic hepatitis b, j interferon cytokine res. 2015 feb;35(2):134-42. doi: 10.1089/jir.2013.0119. (if=3.657)(中科院分区:4区)

40)   fajuan rui, hongli yang, zhaoyang guo, zhengming ge, xinyu hu, lulu zhang, qi xue, haiping chen, yayun xu, meng tan, chengyong qin, zebao he, jie li. derivation and validation of prognostic models for predicting survival outcomes in acute-on-chronic liver failure (aclf) patients. journal of viral hepatitis. 2021 dec;28(12):1719-1728.doi: 10.1111/jvh.13611. (if=3.517)(中科院分区:2区)通讯作者

41)   wang j, huang r, liu j, lai r, liu y, zhu c, qiu y, he z, yin s, chen y, yan x, ding w, zheng q*, jie li*, wu c*. a novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis b patients with nafld. j viral hepat. 2023 apr;30(4):287-296. doi: 10.1111/jvh.13808. (if=3.517)(中科院分区:2区)(共同通讯作者

42)   run zhou†, luping yang†, binbin zhang†, yunpeng gu†, tingting kong†, wei zhang, lei sun, chunlan liu, ningjia kong, jie li*, junping shi*. clinical impact of hepatic steatosis on chronic hepatitis b patients in asia: a systematic review and meta-analysis. journal of viral hepatitis. 2023 oct;30(10):793-802. doi: 10.1111/jvh.13872. (if=3.517)(共同通讯作者(中科院分区:2区)

43)   yawen wan#, shengxia yin#, ming li, minxin mao, jiacheng liu, xin tong, jian wang, jie li*, chao wu*. serum cxcl16 serves as the predictor for liver inflammation functioning through a nkt cell-depend way in chronic hepatitis b patients. journal of viral hepatitis. 2023 (if=3.517)(共同通讯作者(中科院分区:2区)

44)   zhu y, liu c, xu x, ma x, liu j, zhang z, li f, wong dk, fan z, wu c, qi x, jie li. association of diabetes mellitus with all-cause and cause-specific mortality among patients with metabolic-dysfunction-associated fatty liver disease: a longitudinal cohort study. j pers med. 2023 mar 20;13(3):554. doi: 10.3390/jpm13030554. (if=3.508)(中科院分区:3区)

45)   jie li, jun shi, wanhua ren, wei wu, zhi chen. regulatory role of cd4( )cd25 ( )foxp3 ( ) regulatory t cells on il-17-secreting t cells in chronic hepatitis b patients, digestive diseases and sciences. 2014; 59:1475-83. doi: 10.1007/s10620-013-3022-1. (if=3.487)(中科院分区:3区)

46)   hongli yang#, fajuan rui#, rui li#, shengxia yin, qi xue, xinyu hu, yayun xu, chao wu, junping shi*, jie li*, adar1 inhibits hbv dna replication via regulating mir-122-5p in palmitic acid treated hepg2.2.15 cells, diabetes, metabolic syndrome and obesity: targets and therapy. 2022 dec 23;15:4035-4047.doi: 10.2147/dmso.s373385. (if=3.249)(中科院分区:4区)

47)   jie li, matthew s. chang,tram t. tran, mindie h. nguyen, management of chronic hepatitis b in pregnancy, j clin gastroenterol. 2017 oct; 51 (9):789-795. (if=3.174)(中科院分区:3区)

48)   wei wu#, jie li #, feng chen, haihong zhu, guoping peng, zhi chen. circulating th17 cells frequency is associated with the disease progression in hbv infected patients. j gastroenterol hepatol. 2010 apr;25(4):750-7. doi: 10.1111/j.1440-1746.2009.06154.x. (if=3.174)(中科院分区:3区)

49)   jie li, xizhen sun, jianting fang, chuanxi wang, guoqing han, wanhua ren, analysis of intrahepatic total hbv dna, cccdna and serum hbsag level in chronic hepatitis b patients with undetectable serum hbv dna during oral antiviral therapy,  2017 dec;41(6):635-643. doi: 10.1016/j.clinre.2017.03.004. (if=3.189)(中科院分区:4区)

50)   liu j, gong x, lv h, liu s, jiang y, zhu g, ma x, wang j, ye x, gao y,jie li*, chen g*, shi j*. is fatigue related to the severity of liver inflammation in patients with chronic liver disease? a cross-sectional study. bmj open. 2023 apr 20;13(4):e069028.doi: 10.1136/bmjopen-2022-069028. (if=3.006)(中科院分区:3区)共同通讯作者

51)   tingting kong,yunpeng gu,leisun, run zhou, jie li*, junping shi*. association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis. endocrine journal. 2023 oct 30;70(10):959-967. doi: 10.1507/endocrj.ej23-0157. (if=2.86)(中科院分区:4区)共同通讯作者

52)jia-li xu, jia-ping gu, li-yan wang, qian-ru zhu, ning-ning you, jie li*, jie li*, jun-ping shi*. aberrant spontaneous brain activity and its association with cognitive function in non-obese nonalcoholic fatty liver disease: a resting-state fmri study. journal of integrative neuroscience. 2023 jan 4;22(1):8.doi: 10.31083/j.jin2201008. (if=1.8)(中科院分区:4区)共同通讯作者

53)   zebao he, fajuan rui, zhengming ge, rui huang, hongli yang, lingjun ying, haihong zhao, chao wu, jie li. establishment and evaluation of a prediction model of blr for severity in coronavirus disease 2019 (covid-19). infectious diseases & immunity. 2022 

54)   fajuan rui, hongli yang, xinyu hu, qi xue, yayun xu, junping shi*, jie li*. renaming nafld to mafld: advantages and potential changes in diagnosis, pathophysiology,treatment, and management. infectious microbes & diseases2023 (if=1.7)      

55)   brian i. carr*, fanjuan rui*, volkan ince, sezai yilmaz, jie li. comparison of hbv-associated hcc patients from turkey and china cohorts. portal hypertension & cirrhosis, 2023

56)   ming li, xiaoming xu, yong liu, yu geng, chao wu, jie li. global research status and trend in hbv dna mutation from 2003 to 2022: a comprehensive bibliometric view. portal hypertension & cirrhosis, 2023

57)   renling yao, jun chen, jie li. hepatic langerhans cell histiocytosis: report of a rare case. human pathology reports, 2023

58)   li jie#, wang qingzhi#, ni wenjing#, liu chuan, li zhihui*, qi xiaolong*. global health burden of cirrhosis and other chronic liver diseases (clds) due to non-alcoholic fatty liver disease (nafld): a systematic analysis for the global burden of disease study 2019, global transitions 5 (2023) 160-169

59)   xiaoming xu, jiacheng liu, yixuan zhu, fajuan rui, chao wu, jie li. spleen stiffness measurement as a noninvasive assessment in patients with portal hypertension. egastroenterology 2023

1)      2024.01-2026.12,“国家自然科学基金(面上项目)”课题——“高表达bpifa1基因的isg相关中性粒细胞调控新冠上呼吸道黏膜免疫微环境的机制研究”(课题编号92369117)经费:60.0

2)      2022.01-2025.12,“国家自然科学基金(面上项目)”课题——“高脂诱导smad4调控rna编辑酶adar1在乙型肝炎病毒复制中的作用及机制”(课题编号82170609)经费:55.0

3)      2020.01-2023.12,“国家自然科学基金(面上项目)”课题——“il-27调控t-bet转录因子在th17细胞介导的乙型肝炎肝损伤中的作用及机制研究”(课题编号81970545)经费:55.0

4)      2018.01-2020.12,“国家科技重大专项课题(艾滋病和病毒性肝炎等重大传染病防治)”课题——“免疫炎症相关重症乙肝精准诊断标志物的扩大应用”(课题编号2018zx10302206-001-006)经费:30.0

5)      2013.01-2015.12,“国家自然科学基金(青年基金)项目”课题——“il-10调控th17细胞在慢性hbv感染肝损伤中的作用及机制研究”(课题编号81201288)经费:23.0

6)      2021.01-2023.12,“山东省自然科学基金(重点项目)”课题——“il-27抑制th17细胞分化在慢加急性肝衰竭中的作用机制研究及临床应用”(课题编号zr2020kh006)经费:30.0

7)      2017.08-2020.06,“山东省自然科学基金(面上项目)”课题——“kupffer细胞调控th17细胞在hbv感染肝损伤中的作用及机制”(课题编号zr2017mh102)经费:13.0

8)      2019.01-2020.12,“山东省重点研发计划项目“课题——“il-27抑制th17细胞分化的表观遗传分子机制及其在乙型肝炎中的作用”(课题编号2019gsf108145)经费:15.0

9)      2023.09-2026.08,“江苏省自然科学基金(面上项目)“课题——“高脂诱导smad4调控adar1抑制hbv复制的机制研究”(课题编号bk20231118)经费:10.0

10)   2019.06-2020.05,“教育部科技发展中心高校产学研创新基金”课题——“基于大数据技术的脂肪性肝病精准预测模型研与平台构建”(课题编号2018a02002)经费:5.0

11)    2022.06-2023.05,“教育部科技发展中心高校产学研创新基金”课题——“虚拟现实及混合现实技术联合标准化虚拟临床场景教学实践模式在传染病教学中的应用”(课题编号2021ita08002)经费:5.0

12)   2018.06-2020.6,“real-c国际多中心研究”课题——“real-world evidence from the asia liver consortium for hcv经费:20.0

13)   2014.07-2017.07,“中国博士后基金(一等资助)”课题——“通过socs3调控th17细胞在hbv感染肝损伤中的作用”(课题编号)经费:8.0

14)   2014.01-2016.12,“中国肝炎防治基金会项目”课题——“基于jak-stat信号通路研究il-10调控th17细胞分化对肝纤维化大鼠的保护作用及机制”(课题编号cfhpc20131015)经费:5.0

15)   2015.01-2017.01,“传染病诊治国家重点实验室开放基金资助项目”课题——“th17细胞在hbv感染小鼠肝脏免疫损伤中的作用及其调控机制”(课题编号2014kf02)经费:12.0

16)   2022.04-2025.12,“南京市医学重点科技发展项目”课题——“基于深度机器学习构建sars-cov-2疫苗序贯加强免疫后抗原特异性免疫预测体系”(课题编号zkx22028)经费:10.0

17)   2021.01-2022.12,“济南市科技发展计划”课题——“il-27th17细胞介导的乙型病毒性肝炎肝损伤中的作用及机制研究”(课题编号202019079)经费:13.0

18)   2017.09-2020.01,“济南市科技发展计划”课题——“kupffer细胞对th17细胞介导的hbv感染肝损伤的调控作用机制研究”(课题编号201704109)经费:10.0

1)2018急慢性肝病免疫发病机制及分子诊断技术研究与应用,山东医学科技奖二等奖(第一位,1/7

2)2017乙肝肝硬化的发病机制和诊疗技术及应用,山东省科技进步二等奖(第三位,3/8

3)2018乙肝肝硬化及其并发症的关键诊疗技术研发与应用,山东省高等学校科学技术奖一等奖(第四位,4/8

4)2019乙肝肝硬化及其并发症的诊疗技术创新与应用,华夏医学科技奖三等奖(第三位,3/9

5)2023基于免疫评估的慢性乙型肝炎诊疗技术创新与临床应用,江苏医学科技奖二等奖(第一位,1/9


网站地图